Hershey reported an 8% increase in sales of its Ice Breakers mints in the first quarter, driven by the rising use of GLP-1 drugs like Ozempic, which some users say cause bad breath. This trend has boosted demand for breath-freshening products and protein bars, contributing to a more than 10% revenue growth for Hershey in the quarter. Other companies like Lindt and Magnum Ice Cream also see increased sales from GLP-1 users opting for premium snacks. The trend highlights a shift in snacking habits among consumers using these medications.
The SCHD ETF has returned just under 2% in the past month, outperforming the S&P 500 ETF (SPY) by nearly 1%. Year-to-date, about 30 SCHD holdings have more than doubled the returns of SPY, which has returned 9.8%. Additionally, 31 SCHD holdings are t...
Hershey is now considered an attractive investment after a period of underperformance, offering a 3.3% dividend yield. The company is experiencing net sales growth and improving gross margins, driven by pricing strategies and supply chain efficiencie...
